These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 4903342)

  • 41. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 42. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 43. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
    Fischer PA; Schneider E; Jacobi P; Maxion H
    Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206
    [No Abstract]   [Full Text] [Related]  

  • 44. Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
    Sweet RD; Lee JE; McDowell F
    Trans Am Neurol Assoc; 1971; 96():59-65. PubMed ID: 5159130
    [No Abstract]   [Full Text] [Related]  

  • 45. Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase.
    Reid JL; Calne DB; Vakil SD; Allen JG; Davies CA
    J Neurol Sci; 1972 Sep; 17(1):45-51. PubMed ID: 4560435
    [No Abstract]   [Full Text] [Related]  

  • 46. L-dopa therapy in Parkinson's disease.
    Lipman IJ
    Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138
    [No Abstract]   [Full Text] [Related]  

  • 47. [Clinical remarks on the action of intravenous and oral levo-dopa in the treatment of Parkinson's disease (135 cases)].
    Fasano VA; Urciuoli R; Broggi G; Cannella M; Lombard GF
    Neurochirurgie; 1970; 16(2):171-8. PubMed ID: 5451127
    [No Abstract]   [Full Text] [Related]  

  • 48. An analysis of L-dopa-induced dyskinesias in 152 cases of Parkinson's disease.
    Mones RJ; Elizan TS; Siegel GJ
    Neurology; 1970 Apr; 20(4):405-6. PubMed ID: 5535050
    [No Abstract]   [Full Text] [Related]  

  • 49. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456
    [No Abstract]   [Full Text] [Related]  

  • 50. Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.
    Barbeau A
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534982
    [No Abstract]   [Full Text] [Related]  

  • 51. Changes in taste under L-DOPA therapy.
    Siegfried J; Zumstein H
    Z Neurol; 1971; 200(4):345-8. PubMed ID: 4111634
    [No Abstract]   [Full Text] [Related]  

  • 52. Parkinson's disease treated with L-dopa. Three-year follow-up report.
    Mones RJ
    N Y State J Med; 1972 Nov; 72(22):2749-50. PubMed ID: 4510706
    [No Abstract]   [Full Text] [Related]  

  • 53. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
    Campanella G; Pennetta R
    Acta Neurol (Napoli); 1974; 29(3):252-63. PubMed ID: 4417098
    [No Abstract]   [Full Text] [Related]  

  • 54. [Dopamine and abnormal movements].
    Rondot P; Dumas RJ
    Rev Neurol (Paris); 1972 Jul; 127(1):99-113. PubMed ID: 4272134
    [No Abstract]   [Full Text] [Related]  

  • 55. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E; Cerillo A; Tata MR; Decina A
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract]   [Full Text] [Related]  

  • 56. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
    Wycis HT
    Confin Neurol; 1972; 34(2):130-5. PubMed ID: 4666056
    [No Abstract]   [Full Text] [Related]  

  • 57. L-Dopa therapy of Parkinson's disease. (A review of the preliminary experience at West Virginia University).
    Gutmann L; Martin JD; Gutrecht JA
    W V Med J; 1970 Apr; 66(4):109-11. PubMed ID: 5264660
    [No Abstract]   [Full Text] [Related]  

  • 58. Therapeutic uses and side effects of L-dopa.
    Boshes B
    Adv Intern Med; 1972; 18():219-49. PubMed ID: 4576081
    [No Abstract]   [Full Text] [Related]  

  • 59. [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].
    Gauthier G; de Ajuriaguerra J; Simona B; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Neurol (Paris); 1970 Nov; 123(5):297-319. PubMed ID: 5513630
    [No Abstract]   [Full Text] [Related]  

  • 60. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.